-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The protein FOXK2 promotes the survival of ovarian cancer stem cells, according to a Northwestern Medicine study published in the Journal of Clinical Investigation
According to Daniela Matei, MD, blocking this protein can reduce cancer recurrence after initial treatment
"If you use inhibitors to this pathway, the cancer stem cells will die instead of regenerating the tumor," said Matei, who is also a professor of medicine in the Division of Hematology and Oncology
If treated early, ovarian cancer often follows a predictable course of remission after chemotherapy and recurs two years later
In the current study, Matei and her collaborators compared gene expression in ovarian CSCs and normal ovarian cancer cells, looking for genes that were highly expressed in CSCs
The researchers, including first author Yaqi Zhang, a student in the Driskill Life Sciences Graduate Program (DGP), found that FOXK2 directly regulates IREI-alpha, a key sensor that activates the unfolded protein response (UPR)
External stressors to cells—in CSCs, chemotherapy or hypoxia when cells aggregate—can cause protein misfolding
Blocking FOXK2 expression in CSCs, in turn, reduces the activation of UPR-inhibited CSC growth, reducing their so-called "stemness" and making them more like normal cells
These findings represent a possible way to target CSCs in tumors, Matei said
"We are very interested in new inhibitors of this pathway," Matei said
Courtesy of Northwestern University
